{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:14:40Z","timestamp":1784157280997,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment interruption has been found to increase the risk of opportunistic infections and death among HIV-positive adults, posing a challenge to fully realizing antiretroviral therapy (ART). However, it has been observed that short-term interruption (&amp;lt;16 weeks) was not associated with significant increases in adverse clinical events. There remains a dearth of evidence concerning the interruption and resumption of ART after short-term discontinuation in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HIV-positive adults who initiated ART in Jinan between 2004 and 2020 were included in this study. We defined ART interruption as more than 30 consecutive days off ART and used Cox regression to identify predictors of interruption. ART resumption was defined as a return to ART care within 16 weeks following discontinuation, and logistic regression was used to identify barriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,506 participants were eligible. Most of them were male [2,382 (95%)] and homosexual [2,109 (84%)], with a median age of 31 (IQR: 26\u201340) years old. Of all participants, 312 (12.5%) experienced a treatment interruption, and the incidence rate of interruption was 3.2 (95% CI: 2.8\u20133.6) per 100 person-years. A higher risk of discontinuation was observed among unemployed individuals [adjusted hazard ratio (aHR): 1.45, 95% CI: 1.14\u20131.85], with a lower education level (aHR: 1.39, 95% CI: 1.06\u20131.82), those with delayed ART initiation (aHR: 1.43, 95% CI: 1.10\u20131.85), receiving Alafenamide Fumarate Tablets at ART initiation (aHR: 5.19, 95% CI: 3.29\u20138.21). About half of the interrupters resumed ART within 16 weeks, and participants who delayed ART initiation, missed the last CD4 test before the interruption and received the \u201cLPV\/r+NRTIs\u201d regimen before the interruption were more likely to discontinue treatment for the long term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antiretroviral treatment interruption remains relatively prevalent among HIV-positive adults in Jinan, China, and assessing socioeconomic status at treatment initiation will help address this issue. While almost half of the interrupters returned to care within 16 weeks, further focused measures are necessary to reduce long-term interruptions and maximize the resumption of care as soon as possible to avoid adverse clinical events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1137132","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T04:35:17Z","timestamp":1683606917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study"],"prefix":"10.3389","volume":"11","author":[{"given":"Jing","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-015-0515-6","article-title":"Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"76","author":"Collins","year":"2016","journal-title":"Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/QAD.0000000000001373","article-title":"Association between engagement in-care and mortality in HIV-positive persons: a cohort study","volume":"31","author":"Sabin","year":"2017","journal-title":"AIDS."},{"key":"B3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/1060028018758432","article-title":"Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review","volume":"52","author":"Boswell","year":"2018","journal-title":"Ann Pharmacol."},{"key":"B4","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10461-018-2278-z","article-title":"Non-planning impulsivity but not behavioral impulsivity is associated with HIV medication Non-adherence","volume":"23","author":"Dunne","year":"2019","journal-title":"AIDS Behav."},{"key":"B6","first-page":"CD006148","article-title":"Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults","volume":"2006","author":"Pai","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/135965350501000704","article-title":"Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient\/physician choice in patients with hepatitis C virus coinfection?","volume":"10","author":"Mocroft","year":"2005","journal-title":"Antivir Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/apc.2007.0248","article-title":"Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals","volume":"23","author":"Murri","year":"2009","journal-title":"AIDS Patient Care STDS."},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1468-1293.2009.00779.x","article-title":"Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme","volume":"11","author":"Moore","year":"2010","journal-title":"HIV Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1097\/00002030-200010200-00012","article-title":"Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection","volume":"14","author":"Bonhoeffer","year":"2000","journal-title":"AIDS."},{"key":"B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1468-1293.2007.00436.x","article-title":"Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death","volume":"8","author":"Holkmann Olsen","year":"2007","journal-title":"HIV Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/00002030-200205030-00012","article-title":"Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up","volume":"16","author":"Hogg","year":"2002","journal-title":"AIDS."},{"key":"B13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hiv.12322","article-title":"Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons","volume":"17","author":"Ryom","year":"2016","journal-title":"HIV Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1007\/s10461-014-0776-1","article-title":"Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia","volume":"18","author":"Samji","year":"2014","journal-title":"AIDS Behav."},{"key":"B17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12879-015-1036-3","article-title":"People with diagnosed HIV infection not attending for specialist clinical care: UK national review","volume":"15","author":"Curtis","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/QAD.0b013e32834fa15e","article-title":"Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study","volume":"26","author":"Helleberg","year":"2012","journal-title":"AIDS."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1365-3156.2011.02828.x","article-title":"Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review","volume":"16","author":"Katharina","year":"2011","journal-title":"Trop Med Int Health."},{"key":"B20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s10461-016-1644-y","article-title":"Predictors of adult retention in HIV care: a systematic review","volume":"22","author":"Bulsara","year":"2018","journal-title":"AIDS Behav."},{"key":"B21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/09540121.2016.1271389","article-title":"Social determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada","volume":"29","author":"Rachlis","year":"2017","journal-title":"AIDS Care."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1186\/s12889-021-12264-9","article-title":"Factors associated with an interruption in treatment of people living with HIV in USAID-supported states in Nigeria: a retrospective study from 2000-2020","volume":"21","author":"Tomescu","year":"2021","journal-title":"BMC Public Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/hiv.12173","article-title":"Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada","volume":"16","author":"Samji","year":"2015","journal-title":"HIV Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10461-008-9401-5","article-title":"Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions","volume":"13","author":"Das-Douglas","year":"2009","journal-title":"AIDS Behav."},{"key":"B25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/jmv.23297","article-title":"Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy","volume":"84","author":"Routy","year":"2012","journal-title":"J Med Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000000987","article-title":"Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir","volume":"30","author":"Calin","year":"2016","journal-title":"AIDS."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","article-title":"Effect of analytical treatment interruption and re-initiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals","volume":"14","author":"Clarridge","year":"2018","journal-title":"PLoS Pathog."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1172\/JCI120194","article-title":"HIV-1 latent reservoir size and diversity are stable following brief treatment interruption","volume":"128","author":"Salantes","year":"2018","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00285","DOI":"10.1128\/JVI.00285-18","article-title":"Effect of short-term ART interruption on levels of integrated HIV DNA","volume":"92","author":"Strongin","year":"2018","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/ije\/dyp233","article-title":"Cohort profile: The Chinese national free antiretroviral treatment cohort","volume":"39","author":"Ma","year":"2010","journal-title":"Int J Epidemiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e13414","DOI":"10.1371\/journal.pone.0013414","article-title":"Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire","volume":"5","author":"Pasquet","year":"2010","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/QAD.0b013e328305bd77","article-title":"HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy","volume":"22","author":"Steingrover","year":"2008","journal-title":"AIDS."},{"key":"B33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/apc.2012.0439","article-title":"Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for \u2018test and treat' prevention strategy","volume":"27","author":"Guy","year":"2013","journal-title":"AIDS Patient Care STDS."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/QAI.0b013e3181f275fd","article-title":"Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors","volume":"55","author":"Kranzer","year":"2010","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6657112","DOI":"10.1155\/2021\/6657112","article-title":"Mortality and attrition rates within the first year of antiretroviral therapy initiation among people living with HIV in Guangxi, China: an observational cohort study","volume":"2021","author":"Zhu","year":"2021","journal-title":"Biomed Res Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijid.2022.07.037","article-title":"Risk factors for late linkage to care and delayed antiretroviral therapy initiation among adults with HIV in sub-Saharan Africa: a systematic review and meta-analyses","volume":"122","author":"Fuge","year":"2022","journal-title":"Int J Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2648923","DOI":"10.1155\/2016\/2648923","article-title":"Gaps in the continuum of HIV care: long pretreatment waiting time between HIV diagnosis and antiretroviral therapy initiation leads to poor treatment adherence and outcomes","volume":"2016","author":"Su","year":"2016","journal-title":"Biomed Res Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"CD012962","DOI":"10.1002\/14651858.CD012962.pub2","article-title":"Rapid initiation of antiretroviral therapy for people living with HIV","volume":"6","author":"Mateo-Urdiales","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B39","unstructured":"Announcement on the inclusion of 2019 negotiated drugs into the category B scope of the National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance"},{"key":"B40","unstructured":"EACS guidelines (version 9.1. 2018)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11904-007-0027-4","article-title":"Use of pharmacy refill data as a measure of antiretroviral adherence","volume":"4","author":"Grossberg","year":"2007","journal-title":"Curr HIV\/AIDS Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2105\/AJPH.2020.306152","article-title":"Enhanced telehealth case management plus emergency financial assistance for homeless-experienced people living with HIV during the COVID-19 pandemic","volume":"111","author":"Brody","year":"2021","journal-title":"Am J Public Health."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1137132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T04:35:22Z","timestamp":1683606922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1137132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":42,"alternative-id":["10.3389\/fpubh.2023.1137132"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1137132","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1137132"}}